<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38370104</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1937-8688</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>Suppl 2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>The Pan African medical journal</Title><ISOAbbreviation>Pan Afr Med J</ISOAbbreviation></Journal><ArticleTitle>Seroprevalence of poliovirus antibodies in Nigeria: refining strategies to sustain the eradication effort.</ArticleTitle><Pagination><StartPage>2</StartPage><MedlinePgn>2</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.11604/pamj.supp.2023.45.2.38098</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">in 2016, a switch from trivalent oral poliovirus vaccine (OPV) (containing serotypes 1,2,3) to bivalent OPV (types 1,3) was implemented globally. We assessed the seroprevalence of poliovirus antibody levels in selected Nigerian states, before and after the switch, documented poliovirus type2 outbreak responses conducted and ascertained factors associated with immunity gaps based on seroprevalence rates.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">we conducted a secondary analysis of stored serum samples from the 2018 Nigeria National HIV/AIDS Indicator and Impact Survey. Serum from 1,185 children aged 0-119 months residing in one southern and four northern states were tested for serotype-specific PV neutralizing antibodies; seropositivity was a reciprocal titer ≥8. We conducted regression analysis to determine sociodemographic risk factors associated with low seroprevalence using SAS 9.4.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">children aged 24-119 months (pre-switch cohort) had seroprevalence against PV1, PV2, and PV3, of 97.3% (95% CI:96.4-98.2), 93.8% (95% CI:92.2-95.5), and 91.3% (95% CI:89.2-93.4), while children aged &lt;24 months (post-switch) had seroprevalence of 86.0% (95% CI:81.2-90.8), 55.6% (95% CI: 47.7-63.4), and 77.2% (95% CI:71.0-83.4) respectively. Regression analysis showed age &lt;24 months was associated with lower seroprevalence against all PV serotypes, (p&lt;0.0001); females had lower seroprevalence against PV1 (p=0.0184) and PV2 (p=0.0354); northern states lower seroprevalence against PV1 (p=0.0039), while well-water source lower seroprevalence against PV3 (p=0.0288).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">this study showed high seroprevalence rates against PV 1, 2, and 3 in pre-switch children (aged 24-119 months). However, post-switch children (&lt;24 months) had low immunity against PV2 despite outbreak responses. Strategies to increase routine immunization coverage and high-quality polio campaigns can increase immunity against polio virus.</AbstractText><CopyrightInformation>©Omotayo Bolu et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bolu</LastName><ForeName>Omotayo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamu</LastName><ForeName>Usman</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franka</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umeokonkwo</LastName><ForeName>Chukwuma David</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Africa Field Epidemiology Network, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greby</LastName><ForeName>Stacie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Sharla</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainou</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mba</LastName><ForeName>Nwando</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Nigeria Center for Disease Control, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agala</LastName><ForeName>Ndidi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>Wiedad Roodly</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braka</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etapelong</LastName><ForeName>Sume Gerald</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gashu</LastName><ForeName>Tegegne Sisay</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddique</LastName><ForeName>Anisur Rahman</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>United Nations Children Fund, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asekun</LastName><ForeName>Adeyelu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okoye</LastName><ForeName>McPaul</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iriemenam</LastName><ForeName>Nnaemeka</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiesen</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaminathan</LastName><ForeName>Mahesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ihekweazu</LastName><ForeName>Chikwe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nigeria Center for Disease Control, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuaib</LastName><ForeName>Faisal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Uganda</Country><MedlineTA>Pan Afr Med J</MedlineTA><NlmUniqueID>101517926</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009549" MajorTopicYN="N" Type="Geographic">Nigeria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nigeria</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">disease outbreaks</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">immunization</Keyword><Keyword MajorTopicYN="N">polio virus vaccine</Keyword><Keyword MajorTopicYN="N">poliomyelitis</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">serotype</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>20</Day><Hour>11</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>4</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38370104</ArticleId><ArticleId IdType="pmc">PMC10874096</ArticleId><ArticleId IdType="doi">10.11604/pamj.supp.2023.45.2.38098</ArticleId><ArticleId IdType="pii">PAMJ-45-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization Global eradication of poliomyelitis by the year 2000: The Forty-first World Health Assembly. May 13 1988, Accessed September 21, 2021.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative . Declaration Further Milestone for Globally-Coordinated Vaccine Switch in 2016. Global eradication of wild poliovirus type 2 declared. Accessed September 21, 2021.</Citation></Reference><Reference><Citation>Kuehn B. Poliovirus type 3 is eradicated. JAMA. 2019 Dec 17;322(23):2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">31846022</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmi G. Africa declared free from wild polio - but vaccine-derived strains remain. Nature. 2020. Aug 28,</Citation><ArticleIdList><ArticleId IdType="pubmed">32860027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, et al. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine-Worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016 Sep 9;65(35):934–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuma JN, Wilkinson AL, Diop OM, Jorba J, Gardner T, Snider CJ, et al. Surveillance to Track Progress Toward Polio Eradication-Worldwide, 2019-2020. Morbidity and Mortality Weekly Report. 2021 May 7;70(18):667–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9368747</ArticleId><ArticleId IdType="pubmed">33956779</ArticleId></ArticleIdList></Reference><Reference><Citation>National Bureau of Statistics (NBS), United Nations Children Fund (UNICEF) Abuja Nigeria. 2017. Multiple Indicator Cluster Survey 2016-17, Survey Findings Report.</Citation></Reference><Reference><Citation>National Population Commission (NPC) [Nigeria] and ICF . Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF; 2018. 2019 Nigeria Demographic and Health Survey.</Citation></Reference><Reference><Citation>Giwa FJ, Olayinka AT, Ogunshola FT. Seroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria. Vaccine. 2012 Nov 6;30(48):6759–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">23000220</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliyasu Z, Nwaze E, Verma H, Mustapha AO, Weldegebriel G, Gasasira A, et al. Survey of poliovirus antibodies in Kano, Northern Nigeria. Vaccine. 2014 Mar 10;32(12):1414–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24041545</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig KT, Verma H, Iliyasu Z, Mkanda P, Touray K, Johnson T, et al. Role of Serial Polio Seroprevalence Studies in Guiding Implementation of the Polio Eradication Initiative in Kano, Nigeria: 2011-2014. J Infect Dis. 2016 May 1;213(Suppl 3(Suppl 3)):S124–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818560</ArticleId><ArticleId IdType="pubmed">26908720</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba MM, Haruna BA, Ogunmola O, Ambe JP, Shidali NN, Oderinde B, et al. A survey for neutralizing antibodies to the three types of poliovirus among children in maiduguri, Nigeria. J Med Virol. 2012 Apr;84(4):691–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22337311</ArticleId></ArticleIdList></Reference><Reference><Citation>Federal Ministry of Health Nigeria Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) 2018: Technical Report. Abuja. 2020</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized Methods for Detection of Poliovirus Antibodies. In: Martín J, editor. Methods in Molecular Biology. New York, NY: Humana Press; 2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma H, Iliyasu Z, Craig KT, Molodecky NA, Urua U, Jibir BW, et al. Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria. Clin Infect Dis. 2018 Oct 30;67(suppl_1):S103–S109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206109</ArticleId><ArticleId IdType="pubmed">30376090</ArticleId></ArticleIdList></Reference><Reference><Citation>Federal Ministry of Health . Abuja, Nigeria. 2020. Nigeria HIV/AIDS Indicator and Impact Survey: Data Use Manual.</Citation></Reference><Reference><Citation>National Primary Health Care Development Agency Nigeria Polio Weekly Report (Week 50 2018) Abuja, Nigeria. 2018. [unpublished]</Citation></Reference><Reference><Citation>Manyanga D, Byabamazima C, Masvikeni B, Fussum D. Assessment of acute flaccid paralysis surveillance performance in East and Southern African countries 2012 - 2019. Pan Afr Med J. 2020 Jun 8;36:71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7380870</ArticleId><ArticleId IdType="pubmed">32754298</ArticleId></ArticleIdList></Reference><Reference><Citation>The Global Polio Eradication Initiative Assessing Vaccination Coverage Levels Using Clustered Lot Quality Assurance Sampling. April 27 2012, Accessed September 21, 2021.</Citation></Reference><Reference><Citation>World Health Organization . Standard Operating Procedure: Responding to a Poilovirus Event or Outbreak, Version 3.1. Geneva: 2020</Citation></Reference><Reference><Citation>Gidado SO, Nguku PM, Ohuabunwo CJ, Waziri NE, Etsano A, Mahmud MZ, et al. Polio Field Census and Vaccination of Underserved Populations-Northern Nigeria, 2012-2013. MMWR Morb Mortal Wkly Rep. 2013 Aug 23;62(33):663–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4604797</ArticleId><ArticleId IdType="pubmed">23965829</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh M te, Bujaki E, Dolan PT, Smith M, Wahid R, Konz J, et al. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020 May 13;27(5):736–751.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative nOPV2. Accessed November 11 2021.</Citation></Reference><Reference><Citation>World Health Organization First ever vaccine listed under WHO emergency use. November 13 2020, Accessed December 2, 2021.</Citation></Reference><Reference><Citation>Yousafzai MT. Role of Fractional-Dose Intradermal Inactivated Poliovirus Vaccine in Halting Polio Transmission: Finding the Missing Piece for Global Polio Eradication. J Infect Dis. 2018 Nov 5;218(12):1855–1857.</Citation><ArticleIdList><ArticleId IdType="pubmed">29982585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl S, Verma H, Bhatnagar P, Haldar P, Satapathy A, Kumar KNA, et al. Fractional-Dose Inactivated Poliovirus Vaccine Immunization Campaign-Telangana State, India, June 2016. MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):859–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">27559683</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>